Avalo TherapeuticsAVTX
13F holders, Q4 2024 (December 31)33holders +4
7new positions
5sold out
$7.43avg. 13F price*
At the end of Q4 2024, 33 institutions reported holding Avalo Therapeutics Inc. (AVTX) in their 13F filings, up 4 from Q3 2024. 7 opened new positions and 5 sold out. The largest holders were BVF Inc. ($7.7M), Ikarian Capital, LLC ($7.2M) and Orbimed Advisors LLC ($7.2M).
- Company
- Avalo Therapeutics Inc.
- CUSIP
- 05338F306
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $2.9M |
| Exits | 5 | $5.1M |
All 13F filers, Q3 2024 → Q4 2024: 1,439,534 shares bought and 639,287 shares sold, net +800,247 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 33 holders
| BVF Inc. | 0.26% | Add +7.2% | 1,036,679 | $7.7M |
| Ikarian Capital, LLC | 2.06% | Reduce -0.0% | 970,259 | $7.2M |
| Orbimed Advisors LLC | 0.15% | No change | 967,000 | $7.2M |
| Ra Capital Management, L.P. | 0.10% | No change | 967,000 | $7.2M |
| Deep Track Capital, LP | 0.24% | Reduce -10.3% | 867,000 | $6.4M |
| Affinity Asset Advisors, LLC | 0.70% | Add +1123.9% | 550,765 | $4.1M |
| TCG Crossover Management, LLC | 0.35% | No change | 483,000 | $3.6M |
| Commodore Capital LP | 0.26% | No change | 483,000 | $3.6M |
| Vanguard Group Inc. | 0.00% | Add +1499.2% | 165,801 | $1.2M |
| Boothbay Fund Management, LLC | 0.04% | Reduce -0.1% | 163,992 | $1.2M |
| BlackRock, Inc. | 0.00% | Add +40397.0% | 133,235 | $990K |
| Royal Bank of Canada | 0.00% | New | 117,356 | $872K |
| Velan Capital Investment Management LP | 0.71% | New | 109,972 | $817K |
| Geode Capital Management, LLC | 0.00% | Add +937.0% | 104,853 | $779K |
| UBS Group AG | 0.00% | Add +1506.1% | 98,519 | $732K |
| Allostery Investments LP | 1.07% | — | 73,314 | $545K |
| Sio Capital Management, LLC | 0.15% | No change | 71,458 | $531K |
| Bank of Montreal | 0.00% | New | 60,000 | $446K |
| HRT Financial LP | 0.00% | New | 40,000 | $297K |
| Northern Trust Corp. | 0.00% | New | 22,673 | $168K |
| Walleye Capital LLC | 0.00% | New | 19,477 | $145K |
| Marshall Wace, LLP | 0.00% | New | 15,323 | $114K |
| Bank of America Corp. | 0.00% | Add +1.2% | 5,670 | $42K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +998.4% | 4,130 | $31K |
| SBI Securities Co., Ltd. | 0.00% | — | 22 | $163 |
| Morgan Stanley | 0.00% | No change | 10 | $74 |
| BNP Paribas Financial Markets | 0.00% | No change | 4 | $30 |
| JPMorgan Chase & Co. | 0.00% | No change | 2 | $15 |
| Group One Trading LLC | 0.00% | No change | 2 | $15 |
| Osaic Holdings, Inc. | 0.00% | No change | 2 | $14 |
| Parallel Advisors, LLC | 0.00% | No change | 1 | $7 |
| Key Financial Inc | 0.00% | No change | 1 | $7 |
| Activest Wealth Management | 0.00% | No change | 1 | $7 |
"% of holder's portfolio" is AVTX's weight in each manager's 13F, not the share of Avalo Therapeutics Inc. the manager owns.